Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer

References

• Andrade LM, De Fátima Reis C, Maione-Silva L, Anjos JLV, Alonso A, Serpa RC, Marreto RN, Lima EM, Taveira SF. Impact of lipid dynamic behavior on physical stability, in vitro release and skin permeation of genistein-loaded lipid nanoparticles. Eur J Pharm Biopharm, 2014;88:40–7.
   PubMed Web of Science ®Google Scholar
• Battaglia L, Gallarate M, Peira E, Chirio D, Muntoni E, Biasibetti E, Capucchio MT, Valazza A, Panciani PP, Lanotte M. Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies. J Pharm Sci, 2014;103:2157–65.
   PubMed Web of Science ®Google Scholar
• Calderón-Colón X, Patchan MW, Theodore ML, Le HT, Sample JL, Benkoski JJ, Patrone JB. Synthesis of sub-10 nm solid lipid nanoparticles for topical and biomarker detection applications. J Nanopart Res, 2014;16:2252.
   Web of Science ®Google Scholar
• Chen Y, Wan Y, Wang Y, Zhang H, Jiao Z. Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomed, 2011;6:2321.
   PubMed Web of Science ®Google Scholar
• Deepa K, Singha S, Panda T. Doxorubicin nanoconjugates. J Nanosci Nanotechnol, 2014;14:892–904.
   PubMed Web of Science ®Google Scholar
• Dolatabadi JEN, Hamishehkar H, Eskandani M, Valizadeh H. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B: Biointerfaces, 2014;117:21–8.
   PubMed Web of Science ®Google Scholar
• Dolatabadi JEN, Valizadeh H, Hamishehkar H. Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs. Adv Pharm Bull, 2015;5:151.
   PubMed Web of Science ®Google Scholar
• Geetha T, Kapila M, Prakash O, Deol PK, Kakkar V, Kaur IP. Sesamol-loaded solid lipid nanoparticles for treatment of skin cancer. J Drug Target, 2015;23:159–69.
   PubMed Web of Science ®Google Scholar
• Ghaderi S, Ghanbarzadeh S, Hamishehkar H. Evaluation of different methods for preparing nanoparticle containing gammaoryzanol for potential use in food fortification. Pharm Sci, 2015;20:130.
   Google Scholar
• Ghanbarzadeh S, Hariri R, Kouhsoltani M, Shokri J, Javadzadeh Y, Hamishehkar H. Enhanced stability and dermal delivery of hydroquinone using solid lipid nanoparticles. Colloids Surf B: Biointerfaces, 2015;136:1004–10.
   PubMed Web of Science ®Google Scholar
• Grudzinski IP, Bystrzejewski M, Cywinska MA, Kosmider A, Poplawska M, Cieszanowski A, Ostrowska A. Cytotoxicity evaluation of carbon-encapsulated iron nanoparticles in melanoma cells and dermal fibroblasts. J Nanopart Res, 2013;15:1835–52.
   PubMed Web of Science ®Google Scholar
• Ibsen S, Zahavy E, Wrasdilo W, Berns M, Chan M, Esener S. A novel doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy. Pharm Res, 2010;27:1848–60.
   PubMed Web of Science ®Google Scholar
• Kang KW, Chun MK, Kim O, Subedi RK, Ahn SG, Yoon JH, Choi HK. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed: Nanotechnol Biol Med, 2010;6:210–13.
   PubMed Web of Science ®Google Scholar
• Kelidari H, Saeedi M, Akbari J, Morteza-Semnani K, Gill P, Valizadeh H, Nokhodchi A. Formulation optimization and in vitro skin penetration of spironolactone loaded solid lipid nanoparticles. Colloids Surf B: Biointerfaces, 2015;128:473–9.
   PubMed Web of Science ®Google Scholar
• Liu C, Lin W. Systemic co-delivery of doxorubicin and siRNA using nanoparticles conjugated with EGFR-specific targeting peptide to enhance chemotherapy in ovarian tumor bearing mice. J Nanopart Res, 2013;15:1956–69.
   Web of Science ®Google Scholar
• Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm, 2007;328:191–5.
   PubMed Web of Science ®Google Scholar
• Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco MR. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm, 2000;210:61–7.
   PubMed Web of Science ®Google Scholar
• Minaei A, Sabzichi M, Ramezani F, Hamishehkar H, Samadi N. Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells. Mol Biol Rep, 2016;43:99–105.
   PubMed Web of Science ®Google Scholar
• Müller R, Radtke M, Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm, 2002;242:121–8.
   PubMed Web of Science ®Google Scholar
• Mura S, Bui DT, Couvreur P, Nicolas J. Lipid prodrug nanocarriers in cancer therapy. J Control Rel, 2015;208:25–41.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res, 2009;11:R12.
   PubMed Web of Science ®Google Scholar
• Omidi Y, Barar J. Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. Bioimpacts, 2014;4:55.
   PubMedGoogle Scholar
• Pardeshi C, Rajput P, Belgamwar V, Tekade A, Patil G, Chaudhary K, Sonje A. Solid lipid based nanocarriers: an overview/Nanonosači na bazi čvrstih lipida: Pregled. Acta Pharm, 2012;62:433–72.
   PubMed Web of Science ®Google Scholar
• Park JM, Lee SY, Lee GH, Chung EY, Chang KM, Kwak BK, Kuh HJ, Lee J. Design and characterisation of doxorubicin-releasing chitosan microspheres for anti-cancer chemoembolisation. J Microencapsul, 2012;29:695–705.
   PubMed Web of Science ®Google Scholar
• Pezeshki A, Ghanbarzadeh B, Mohammadi M, Fathollahi I, Hamishehkar H. Encapsulation of vitamin A palmitate in nanostructured lipid carrier (NLC)-effect of surfactant concentration on the formulation properties. Adv Pharm Bull, 2014;4:563.
   PubMedGoogle Scholar
• Polegato B, Minicucci M, Azevedo P, Carvalho R, Chiuso-Minicucci F, Pereira E, Paiva S, Zornoff L, Okoshi M, Matsubara B. Acute doxorubicin-induced cardiotoxicity is associated with matrix metalloproteinase-2 alterations in rats. Cell Physiol Biochem, 2015;35:1924–33.
   PubMed Web of Science ®Google Scholar
• Rostami E, Kashanian S, Azandaryani AH, Faramarzi H, Dolatabadi JEN, Omidfar K. Drug targeting using solid lipid nanoparticles. Chem Phys Lipids, 2014;181:56–61.
   PubMed Web of Science ®Google Scholar
• Serpe L, Catalano M, Cavalli R, Ugazio E, Bosco O, Canaparo R, Muntoni E, Frairia R, Gasco M, Eandi M. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm, 2004;58:673–80.
   PubMed Web of Science ®Google Scholar
• Sharifi S, Barar J, Hejazi MS, Samadi N. Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells. Adv Pharm Bull, 2015;5:351.
   PubMed Web of Science ®Google Scholar
• Shen H, Shi S, Zhang Z, Gong T, Sun X. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells. Stem Cells (CSCs), 2015;5:756.
   Google Scholar
• Simões M, Sousa J, Pais A. Skin cancer and new treatment perspectives: a review. Cancer Lett, 2015;357:8–42.
   PubMed Web of Science ®Google Scholar
• Stauffer RG, Mohammad M, Singh AT. Novel nanoscale delivery particles encapsulated with anticancer drugs, all-trans retinoic acid or curcumin, enhance apoptosis in lymphoma cells predominantly expressing CD20 antigen. Anticancer Res, 2015;35:6425–9.
   PubMed Web of Science ®Google Scholar
• Susa M, Iyer AK, Ryu K, Hornicek FJ, Mankin H, Amiji MM, Duan Z. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer, 2009;9:399.
   PubMed Web of Science ®Google Scholar
• Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Design and characterization of astaxanthin-loaded nanostructured lipid carriers. Innovat Food Sci Emerg Technol, 2014;26:366–74.
   Web of Science ®Google Scholar
• Taveira SF, De Santana DC, Araújo LM, Marquele-Oliveira F, Nomizo A, Lopez RF. Effect of iontophoresis on topical delivery of doxorubicin-loaded solid lipid nanoparticles. J Biomed Nanotechnol, 2014;10:1382–90.
   PubMed Web of Science ®Google Scholar
• Toraya-Brown S, Sheen MR, Zhang P, Chen L, Baird JR, Demidenko E, Turk MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S. Local hyperthermia treatment of tumors induces CD8+ T cell-mediated resistance against distal and secondary tumors. Nanomed: Nanotechnol Biol Med, 2014;10:1273–85.
   PubMed Web of Science ®Google Scholar
• Wang S, Chen T, Chen R, Hu Y, Chen M, Wang Y. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm, 2012;430:238–46.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther, 2006;317:1372–81.
   PubMed Web of Science ®Google Scholar
• Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res, 2005;65:613–21.
   PubMed Web of Science ®Google Scholar
• Zheng L, Gou M, Zhou S, Yi T, Zhong Q, Li Z, He X, Chen X, Zhou L, Wei Y. Antitumor activity of monomethoxy poly (ethylene glycol)-poly (ɛ-caprolactone) micelle-encapsulated doxorubicin against mouse melanoma. Oncol Rep, 2011;25:1557–64.
   PubMed Web of Science ®Google Scholar